Physician profile
Vineet Sood
NPI 1306861133
$4,870.82
in general payments reported to CMS, 2019-2025
35 companies · $98.14 in 2025
The $98.14 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,032 · 2020: $396 · 2021: $430 · 2022: $1,094 · 2023: $943 · 2024: $878 · 2025: $98.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,266.71 | 2019-2024 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,155.12 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.37 | 2019-2024 | Ofev |
| Genzyme Corporation | $210.06 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $202.70 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $190.54 | 2019-2024 | Zerbaxa, Dificid, Recarbrio |
| Mylan Specialty L.P. | $161.18 | 2019-2023 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $131.81 | 2021-2024 | Dupixent |
| Grifols USA, LLC | $124.00 | 2019-2024 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $103.87 | 2020-2021 | |
| United Therapeutics Corporation | $96.49 | 2021-2023 | Tyvaso |
| Harmony Biosciences LLC | $79.14 | 2024 | |
| Insmed, INC. | $73.92 | 2019-2023 | Arikayce |
| Shionogi INC | $66.66 | 2022-2023 | Fetroja |
| Inogen, INC. | $63.76 | 2022-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $61.02 | 2019-2023 | Xolair |
| La Jolla Pharmaceutical Company | $58.10 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $56.81 | 2019-2022 | |
| Abbvie INC. | $55.36 | 2021-2023 | Avycaz, Teflaro |
| Sunovion Pharmaceuticals INC. | $54.11 | 2019 | |
| Baxter Healthcare | $52.32 | 2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System |
| Electromed, INC. | $51.39 | 2023-2024 | Smartvest |
| Melinta Therapeutics, LLC | $41.26 | 2022 | |
| Inspire Medical Systems, INC. | $36.00 | 2023-2025 | Inspire |
| Mallinckrodt Hospital Products INC. | $35.48 | 2020-2023 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $34.41 | 2020-2023 | Glassia |
| Teva Pharmaceuticals USA, INC. | $29.66 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $28.33 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $20.95 | 2020 | |
| Avadel Cns Pharmaceuticals, LLC | $20.43 | 2024 | Lumryz |
| Philips North America LLC | $19.69 | 2019 | |
| Vifor Pharma, INC. | $18.39 | 2025 | Veltassa |
| Quidel Corporation | $11.68 | 2019 | |
| Allergan, INC. | $11.15 | 2019 | |
| Gilead Sciences, INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vineet Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.